PDS Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
PDS Biotechnology has a total shareholder equity of $26.1M and total debt of $23.7M, which brings its debt-to-equity ratio to 90.6%. Its total assets and total liabilities are $59.4M and $33.3M respectively.
Key information
90.6%
Debt to equity ratio
US$23.67m
Debt
Interest coverage ratio | n/a |
Cash | US$56.56m |
Equity | US$26.13m |
Total liabilities | US$33.26m |
Total assets | US$59.39m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EU6's short term assets ($59.1M) exceed its short term liabilities ($13.6M).
Long Term Liabilities: EU6's short term assets ($59.1M) exceed its long term liabilities ($19.6M).
Debt to Equity History and Analysis
Debt Level: EU6 has more cash than its total debt.
Reducing Debt: EU6 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EU6 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EU6 has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 30.8% each year.